GM-CSF + Naxitamab clinical trials

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

This study is for children and adults with a type of high-risk neuroblastoma that hasn't fully responded to previous treatments. It investigates a new approach using two medicines, Naxitamab and GM-CSF, to see if they can help manage the condition.